Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.55 |
| ▸ | CCR2 | P41597 | 14/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.44 |
| ▸ | CCR4 | P51679 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18406849 | 0.94 | CCR2 (0.57) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL1189926 | 0.88 | CYP2C9 (0.72) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL12040697 | 0.84 | CYP2C9 (0.77) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL18411608 | 0.83 | CCR2 (0.73) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL306156 | 0.79 | MEN1 (0.60) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL12040901 | 0.79 | CYP2C9 (0.49) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL12040892 | 0.79 | CYP2C9 (0.49) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL10223215 | 0.78 | MEN1 (0.59) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL12594353 | 0.77 | MEN1 (0.50) | CYP2C9CCR2CYP3A4MEN1LMNA | |
| SCHEMBL12594325 | 0.77 | MEN1 (0.50) | CYP2C9CCR2CYP3A4MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745312-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170022205-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9394307-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-8546408-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022205-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CYP2C9 1281/4885CCR2 1/4885CYP3A4 1134/4885 |
| US-20110319433-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | CYP2C9 1281/4885CCR2 1/4885CYP3A4 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.